How to use previously published material to save time and money during approval.
Since 1984, the 505(B)(2) Mechanism has given companies a streamlined path to drug product approval with fewer required studies and without a right of reference, relying instead on previously published material.
In this webinar, we discuss which candidates are best suited for 505(B)(2), and how to to successfully use the 505(b)(2) mechanism for approval.
You’ll learn:
290 Turnpike Road, Suite 200
Westborough, MA 01581
(508) 926-8330
info@thefdagroup.comProprietary talent selection of former FDA and industry professionals amplified by a corporate culture of responsiveness and execution.
290 Turnpike Road, Suite 200
Westborough, MA 01581
US Toll-Free: 1-833-FDA-GROUP
International: +001 508 926 8330
The FDA Group will not be liable for any errors or omissions in this information nor for the availability of this information. The owner will not be liable for any losses, injuries, or damages from the display or use of this information. Privacy Policy.